5-hydroxytryptamine receptor 2A. Every medicine in our data that ChEMBL or the Guide to Pharmacology records as acting on this protein, with the source for each and its current clinical trials on this site.
| Medicine | How it acts | Source | Current trials here |
|---|---|---|---|
| Psilocybin CHEMBL194378 |
Serotonin 2a (5-HT2a) receptor agonist Agonist Small molecule |
ChEMBL only | 43 |
| Olanzapine CHEMBL715 |
Serotonin 2a (5-HT2a) receptor antagonist Antagonist Small molecule |
✓ Both | 19 |
| Quetiapine CHEMBL716 |
Serotonin 2a (5-HT2a) receptor antagonist Antagonist Small molecule |
✓ Both | 11 |
| Clozapine CHEMBL42 |
Serotonin 2a (5-HT2a) receptor antagonist Antagonist Small molecule |
✓ Both | 8 |
| Risperidone CHEMBL85 |
Serotonin 2a (5-HT2a) receptor antagonist Antagonist Small molecule |
✓ Both | 8 |
| Aripiprazole CHEMBL1112 |
Serotonin 2a (5-HT2a) receptor antagonist Antagonist Small molecule |
✓ Both | 7 |
| Lumateperone CHEMBL3306803 |
Serotonin 2a (5-HT2a) receptor antagonist Antagonist Small molecule |
✓ Both | 5 |
| Trazodone CHEMBL621 |
Serotonin 2a (5-HT2a) receptor antagonist Antagonist Small molecule |
✓ Both | 5 |
| Brexpiprazole CHEMBL2105760 |
Serotonin 2a (5-HT2a) receptor antagonist Antagonist Small molecule |
ChEMBL only | 3 |
| Iloperidone CHEMBL14376 |
Serotonin 2a (5-HT2a) receptor antagonist Antagonist Small molecule |
ChEMBL only | 3 |
| Mirtazapine CHEMBL654 |
Serotonin 2a (5-HT2a) receptor antagonist Antagonist Small molecule |
✓ Both | 3 |
| Haloperidol CHEMBL54 |
Serotonin 2a (5-HT2a) receptor antagonist Antagonist Small molecule |
✓ Both | 2 |
| Lurasidone CHEMBL1237021 |
Serotonin 2a (5-HT2a) receptor antagonist Antagonist Small molecule |
✓ Both | 2 |
| Paliperidone Palmitate CHEMBL2107360 |
Serotonin 2a (5-HT2a) receptor antagonist Antagonist Small molecule |
ChEMBL only | 2 |
“Both” means ChEMBL and the Guide to Pharmacology each record this medicine acting on this protein; “only” means one source records it and the other does not (often because it lists fewer secondary targets). The Guide to Pharmacology adds a medicine here only when this protein is its primary target. Medicines without a link have no page on this site yet.
| Disease | Medicines tested | Furthest trial phase |
|---|---|---|
| Major depressive disorder | 8 | Phase 3 |
| Bipolar disorder | 7 | Phase 3 |
| Alzheimer disease | 6 | Phase 3 |
| Bipolar I disorder | 6 | Phase 3 |
| Depressive disorder | 6 | Phase 3 |
| Agitation | 5 | Phase 3 |
| Borderline personality disorder | 5 | Phase 3 |
| Irritability | 5 | Phase 3 |
| Alcohol dependence | 5 | Phase 3 |
| Post-traumatic stress disorder | 5 | Phase 3 |
| Schizoaffective disorder | 5 | Phase 3 |
| Intellectual disability | 4 | Phase 3 |
| Anxiety | 4 | Phase 3 |
| Dementia | 4 | Phase 3 |
| Insomnia | 4 | Phase 3 |
From ChEMBL's drug-disease records, which draw on trial registries. A trial phase is not an approval; approved uses are on each medicine's page from the regulators' own records.
Which medicines act on this protein comes from two independent, expert-curated sources: ChEMBL's mechanism-of-action records (via the Open Targets Platform) and the IUPHAR/BPS Guide to PHARMACOLOGY. Each row says which of them lists it. Data from them is shared here under their share-alike licences (CC BY-SA 3.0 and 4.0).
A job re-reads both sources every 30 days. Medicines are matched to our pages by exact name or a ChEMBL-curated synonym, and to the Guide to Pharmacology by ChEMBL ID or exact name, never by a close spelling. No AI drafting. See our methodology. The Open Targets data on this page was last retrieved on 30 Sep 2026. How every register is built: methodology · fixes we have made: corrections log.
